top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

0.4756 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
From KALA BIO, Inc.
Via GlobeNewswire
InvestorNewsBreaks – KALA BIO, Inc. (NASDAQ: KALA) Implements 1-For-50 Reverse Stock Split
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
KALA BIO Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on May 11, 2026 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI... 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Younet.ai, a Toronto-based AI technology company specializing in enterprise-grade private LLM solutions,... 
Via Newsfile
Topics Artificial Intelligence
News headline image
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$167 Billion Invested in Biotech R&D is Underserved by AI, Offering Huge Opportunity for New On-Premises AI Infrastructure Platform from KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Settles Approximately $10.6 million of Debt
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companies 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page